BRILINTA: payments to doctors
Payments that named BRILINTA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $5.7M
- Providers
- 28,381
- Transactions
- 109,912
- Average per transaction
- $52
The per-transaction average — $52 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 28,381 providers the average total is $201, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| AstraZeneca | $5,527,434 | 96.7% |
| Astrazeneca AB | $97,227 | 1.7% |
| Astrazeneca UK Limited | $91,583 | 1.6% |
| Acerta Pharma LLC | $1,232 | 0.0% |